These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38198026)

  • 1. Anticipating the future of the COVID-19 pandemic: insights into the emergence of SARS-CoV-2 variant JN.1 and its projected impact on older adults.
    Quarleri J; Delpino MV; Galvan V
    Geroscience; 2024 Jun; 46(3):2879-2883. PubMed ID: 38198026
    [No Abstract]   [Full Text] [Related]  

  • 2. Unveiling the emergence of SARS-CoV-2 JN.1 sub-variant: Insights from the first cases at Charles Nicolle Hospital, Tunisia.
    Hamzaoui Z; Ferjani S; Kanzari L; Ben Ali R; Charaa L; Landolsi I; Medini I; Chammam S; Abid S; Ferjani A; Kebaier D; Fakhfakh A; Bouslah Z; Ben Sassi M; Trabelsi S; Boutiba-Ben Boubaker I
    Acta Microbiol Immunol Hung; 2024 Jul; 71(2):165-171. PubMed ID: 38717854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JN.1 variant in enduring COVID-19 pandemic: is it a variety of interest (VoI) or variety of concern (VoC)?
    Kamble P; Daulatabad V; Singhal A; Ahmed ZS; Choubey A; Bhargava S; John NA
    Horm Mol Biol Clin Investig; 2024 Jun; 45(2):49-53. PubMed ID: 38622986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving immune evasion and transmissibility of SARS-CoV-2: The emergence of JN.1 variant and its global impact.
    Ou G; Yang Y; Zhang S; Niu S; Cai Q; Liu Y; Lu H
    Drug Discov Ther; 2024 Mar; 18(1):67-70. PubMed ID: 38382991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Projecting the Impact of SARS-CoV-2 Variants and the Vaccination Program on the Fourth Wave of the COVID-19 Pandemic in South Korea.
    Shim E
    Int J Environ Res Public Health; 2021 Jul; 18(14):. PubMed ID: 34300029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics and clinical manifestations of patients, including organ transplant patients, during the surge of JN.1: Insights from Saudi Arabia.
    Obeid DA; Al-Qahtani AA; Almaghrabi RS; Alahideb BM; Alharbi LA; AlAbdulkareem MA; Almadi TM; Alsanea MS; Althawadi SI; Altamimi SA; Alhamlan FS
    J Infect Public Health; 2024 Jul; 17(7):102452. PubMed ID: 38820895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. As COVID-19 Cases Surge, Here's What to Know About JN.1, the Latest SARS-CoV-2 "Variant of Interest".
    Rubin R
    JAMA; 2024 Feb; 331(5):382-383. PubMed ID: 38214935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The COVID-19 Pandemic: SARS-CoV-2 Structure, Infection, Transmission, Symptomology, and Variants of Concern.
    Guest PC; Kesharwani P; Butler AE; Sahebkar A
    Adv Exp Med Biol; 2023; 1412():3-26. PubMed ID: 37378759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent insights into SARS-CoV-2 omicron variant.
    Silva SJRD; Kohl A; Pena L; Pardee K
    Rev Med Virol; 2023 Jan; 33(1):e2373. PubMed ID: 35662313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The emergence of Covid-19: evolution from endemic to pandemic.
    Ahsan H; Arif A; Ansari S; Khan FH
    J Immunoassay Immunochem; 2022 Jan; 43(1):22-32. PubMed ID: 34672900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 variant biology and immune evasion.
    Zaidi AK; Singh RB
    Prog Mol Biol Transl Sci; 2024; 202():45-66. PubMed ID: 38237990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral immune escape by current SARS-CoV-2 variants BA.2.86 and JN.1, December 2023.
    Jeworowski LM; Mühlemann B; Walper F; Schmidt ML; Jansen J; Krumbholz A; Simon-Lorière E; Jones TC; Corman VM; Drosten C
    Euro Surveill; 2024 Jan; 29(2):. PubMed ID: 38214083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence of SARS-CoV-2 Omicron Variant JN.1 in Tamil Nadu, India - Clinical Characteristics and Novel Mutations.
    Selvavinayagam ST; Sankar S; Yong YK; Murugesan A; Suvaithenamudhan S; Hemashree K; Rajeshkumar M; Kumaresan A; Pandey RP; Shanmugam S; Arthydevi P; Kumar MS; Gopalan N; Kannan M; Cheedarla N; Tan HY; Zhang Y; Larsson M; Balakrishnan P; Velu V; Byrareddy SN; Shankar EM; Raju S
    medRxiv; 2024 Apr; ():. PubMed ID: 38699322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Emergence of the Omicron (B.1.1.529) SARS-CoV-2 Variant: What is the Impact on the Continued Pandemic?
    Al-Tawfiq JA; Hoang VT; Le Bui N; Chu DT; Memish ZA
    J Epidemiol Glob Health; 2022 Jun; 12(2):143-146. PubMed ID: 35089588
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
    Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
    Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural dynamics of SARS-CoV-2 variants: A health monitoring strategy for anticipating Covid-19 outbreaks.
    Fantini J; Yahi N; Azzaz F; Chahinian H
    J Infect; 2021 Aug; 83(2):197-206. PubMed ID: 34089757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omicron variants of SARS-CoV-2: Epidemiological and clinical insights from a tertiary care center in Saudi Arabia.
    Dubaie B; Aldayel A; Alwethinani S; Alhuthil R; Alhamlan F; Alghamdi S; Alsuhaibani M; Aljumaah S; AlYabes O; AlBanyan E; Al-Hajjar S
    J Infect Public Health; 2024 Jun; 17(6):961-966. PubMed ID: 38608457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next-generation treatments: Immunotherapy and advanced therapies for COVID-19.
    Arevalo-Romero JA; Chingaté-López SM; Camacho BA; Alméciga-Díaz CJ; Ramirez-Segura CA
    Heliyon; 2024 Mar; 10(5):e26423. PubMed ID: 38434363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study.
    Moustsen-Helms IR; Bager P; Larsen TG; Møller FT; Vestergaard LS; Rasmussen M; Hansen CH;
    Lancet Infect Dis; 2024 May; ():. PubMed ID: 38761806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of cross-reactive immunity on the emergence of SARS-CoV-2 variants.
    Thompson RN; Southall E; Daon Y; Lovell-Read FA; Iwami S; Thompson CP; Obolski U
    Front Immunol; 2022; 13():1049458. PubMed ID: 36713397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.